Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022

Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022

Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022

Summary

Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability.


Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/cebranopadol-neuropathic-pain-forecast-and-market-analysis-to-2022


New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.

Cebranopadol (GRT-6005) is a small-molecule opioid analgesic that is being developed by Grnenthal for the treatment of moderate to severe chronic pain conditions. In December 2010, Grnenthal entered into a licensing agreement with Forest Laboratories for the co-development and commercialization of cebranopadol and its follow-on compound, GRT-6006. The drug is currently in Phase IIb of clinical development for PDN, and is also in Phase III of development for cancer pain, as well as in Phase II for chronic nociceptive pain, moderate to severe pain...

Similar Essays